ROCKVILLE, Md., Dec. 7, 2017 /PRNewswire/ –RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its year end letter to shareholders. The letter…
